CYCLOPHARM LIMITED - Announcements

1.52%

97.5¢

Market Cap $108.3M

Technology Scientific & Technical Instruments

Cyclopharm Limited is an Australia-based radiopharmaceutical company. The Company's... Cyclopharm Limited is an Australia-based radiopharmaceutical company. The Company's principal activity is engaged in the manufacture and sale of medical equipment and radiopharmaceuticals, including associated research and development and distribution of third-party products to the diagnostic imaging sector. Its segments include Technegas and Molecular Imaging. The Technegas segment is a supplier of diagnostic equipment and consumables used by physicians in the detection of pulmonary embolism and a distributor of products to the diagnostic imaging sector. The Molecular Imaging segment produces radiopharmaceuticals to be used by physicians in the detection of cancer, neurological disorders and cardiac disease. The Company uses Technegas technology, which is a structured ultra-fine dispersion of radioactive labelled carbon, produced by using driedTechnetium-99m in a carbon crucible. The Company distributes its products in approximately 65 countries.More

Corporate Spotlight
Not Yet Available

Are you a Company Director ?
Put your Investment Case to Hotcopper's 700K monthly unique visitors.

Claim your IR profile

See benefits

Announcements

Filter Results

All Price Sensitive Only

Filters [Clear]

Price Sensitive: Yes

CYC	Announcement of buy-back - Appendix 3C	PRICE SENSITIVE	29/05/18	265.23KB	Share
CYC	CYC 2018 AGM Presentation	PRICE SENSITIVE	29/05/18	1.14MB	Share
CYC	Managing Director's Address to Shareholders	PRICE SENSITIVE	29/05/18	179.05KB	Share
CYC	Chairman's Address to Shareholders	PRICE SENSITIVE	29/05/18	380.36KB	Share
CYC	Better Defining Airways Disease with Technegas	PRICE SENSITIVE	17/05/18	188.86KB	Share
CYC	Cyclopharm Acquires Scandinavian Distribution Business	PRICE SENSITIVE	07/05/18	359.87KB	Share
CYC	40 Patient Milestone Achieved For Technegas USFDA Trial	PRICE SENSITIVE	29/03/18	376.93KB	Share
CYC	Preliminary Final Report	PRICE SENSITIVE	26/02/18	569.46KB	Share
CYC	Dividend/Distribution - CYC	PRICE SENSITIVE	26/02/18	23.99KB	Share
CYC	CYC CEO Presentation 2017 Australian Microcap Conference	PRICE SENSITIVE	18/10/17	678.12KB	Share
CYC	Technegas USFDA Clinical Trial - Patient Enrolment Underway	PRICE SENSITIVE	26/09/17	492.13KB	Share
CYC	Cyclopharm acquires European distribution business	PRICE SENSITIVE	20/09/17	96.62KB	Share
CYC	Advancing Molecular Imaging in NSW	PRICE SENSITIVE	19/09/17	118.6KB	Share
CYC	Half Yearly Report and Accounts	PRICE SENSITIVE	28/08/17	1.19MB	Share
CYC	Nuclear imaging trial aiming to clear up airway diagnosis	PRICE SENSITIVE	18/08/17	120.41KB	Share
CYC	CYC Entitlement Offer Booklet	PRICE SENSITIVE	14/06/17	2.31MB	Share
CYC	Entitlement Offer	PRICE SENSITIVE	05/06/17	1.43MB	Share
CYC	CYC - Positive Results of China Clinical Trial	PRICE SENSITIVE	01/06/17	64.64KB	Share
CYC	Announcement of buy-back - Appendix 3C	PRICE SENSITIVE	09/05/17	120.24KB	Share
CYC	Managing Director's Address to Shareholders	PRICE SENSITIVE	09/05/17	171.02KB	Share
CYC	Cyclopharm Amended 2016 Preliminary Financial Report	PRICE SENSITIVE	27/02/17	922.78KB	Share
CYC	Preliminary Final Report	PRICE SENSITIVE	22/02/17	1.03MB	Share
CYC	CYC 2016 PRELIMINARY HEADLINE UPDATE-RECORD RESULTS	PRICE SENSITIVE	06/02/17	108.03KB	Share
CYC	CYC Achieves USFDA Agreement For Technegas Trial Design	PRICE SENSITIVE	23/11/16	125.4KB	Share
CYC	Cyclopharm Business Update on Significant Milestones-CYC.AX	PRICE SENSITIVE	13/10/16	142.01KB	Share
CYC	Appendix 4D and Half Year Accounts-CYC.AX	PRICE SENSITIVE	19/08/16	1.95MB	Share
CYC	CYC Signs Agreement with the Canadian Association of Nuc Med-CYC.AX	PRICE SENSITIVE	27/06/16	546.06KB	Share
CYC	Trading Update & Record Technegas Order Received from China-CYC.AX	PRICE SENSITIVE	21/06/16	330.68KB	Share
CYC	Announcement of buy-back - Appendix 3C-CYC.AX	PRICE SENSITIVE	11/05/16	235.19KB	Share
CYC	Cyclopharm to Proceed Independently with FDA Trials-CYC.AX	PRICE SENSITIVE	10/05/16	151.49KB	Share
CYC	Preliminary Final Report	PRICE SENSITIVE	24/02/16	1.12MB	Share
CYC	Technegas COPD Trial Update	PRICE SENSITIVE	29/01/16	289.27KB	Share
CYC	Cyclopharm receives insurance settlement	PRICE SENSITIVE	31/12/15	208.49KB	Share
CYC	Cyclopharm signs Term Sheet with Jubilant Draximage	PRICE SENSITIVE	14/09/15	147.71KB	Share
CYC	Half Yearly Report and Accounts	PRICE SENSITIVE	26/08/15	868.83KB	Share
CYC	Preliminary Final Report	PRICE SENSITIVE	19/02/15	760.57KB	Share
CYC	Update on Cyclotron Facility	PRICE SENSITIVE	16/09/14	194.95KB	Share
CYC	Half Yearly Report and Accounts	PRICE SENSITIVE	29/08/14	496.75KB	Share
CYC	Results of Mediation	PRICE SENSITIVE	26/08/14	194.73KB	Share
CYC	Cyclotron Facility Suffers Significant Water Damage	PRICE SENSITIVE	20/06/14	114KB	Share
CYC	Cyclopharm to cease Cyclotron commercial operations	PRICE SENSITIVE	28/03/14	267.79KB	Share
CYC	Preliminary Final Report	PRICE SENSITIVE	28/02/14	567.12KB	Share
CYC	Japanese Regulatory Approval received	PRICE SENSITIVE	25/10/13	212.91KB	Share
CYC	Half Yearly Report and Accounts	PRICE SENSITIVE	28/08/13	332.9KB	Share
CYC	Technegas May Facilitate Earlier Diagnosis of COPD	PRICE SENSITIVE	02/05/13	403.01KB	Share
CYC	Cyclopharm Develops New Nuclear Medicine Technology	PRICE SENSITIVE	18/04/13	220.55KB	Share
CYC	Preliminary Final Report	PRICE SENSITIVE	26/02/13	492.14KB	Share
CYC	Technegas Clinical Trial - First Patient Enrolled	PRICE SENSITIVE	19/11/12	95.71KB	Share
CYC	Offer Booklet	PRICE SENSITIVE	09/11/12	62.96KB	Share
CYC	Renounceable Issue	PRICE SENSITIVE	09/11/12	66.15KB	Share
CYC	Trading Halt	PRICE SENSITIVE	06/11/12	41.49KB	Share
CYC	Half Yearly Report and Accounts	PRICE SENSITIVE	30/08/12	341.41KB	Share
CYC	Cyclopharm to Establish Operations in Queensland	PRICE SENSITIVE	24/08/12	90.97KB	Share
CYC	Cyclopharm Files Claim Against ANSTO	PRICE SENSITIVE	28/06/12	87.13KB	Share
CYC	Preliminary Final Report	PRICE SENSITIVE	29/02/12	329.52KB	Share
CYC	Cyclopharm Receives Approval from United States FDA	PRICE SENSITIVE	13/12/11	334.42KB	Share
CYC	Offer Booklet for Renounceable Rights Issue	PRICE SENSITIVE	18/11/11	62.59KB	Share
CYC	Renounceable Rights Issue and Sale of Unmarketable Parcels	PRICE SENSITIVE	04/11/11	61.78KB	Share
CYC	Renewal of Debt Facility with National Australia Bank	PRICE SENSITIVE	03/11/11	97.31KB	Share
CYC	Half Yearly Report and Accounts	PRICE SENSITIVE	31/08/11	195.46KB	Share
CYC	Trading Update	PRICE SENSITIVE	29/07/11	207.81KB	Share
CYC	Preliminary Final Report	PRICE SENSITIVE	28/02/11	395.04KB	Share
CYC	Clinical Protocol Approval from US FDA	PRICE SENSITIVE	22/02/11	88.25KB	Share
CYC	Cyclopet sells commercial FDG doses	PRICE SENSITIVE	16/12/10	96.17KB	Share
CYC	Cyclopet receives TGA License	PRICE SENSITIVE	03/12/10	97.34KB	Share
CYC	Half Yearly Report and Accounts	PRICE SENSITIVE	31/08/10	1.38MB	Share
CYC	Regulatory Approval in China	PRICE SENSITIVE	25/05/10	91.24KB	Share
CYC	Preliminary Final Report	PRICE SENSITIVE	25/02/10	337.69KB	Share
CYC	Cyclopharm settles claim for US$1.8m	PRICE SENSITIVE	11/12/09	94.45KB	Share
CYC	Cyclotron delivered to Macquarie University Hospital	PRICE SENSITIVE	09/11/09	93.01KB	Share
CYC	Half Yearly Report and Accounts	PRICE SENSITIVE	27/08/09	157.57KB	Share
CYC	Cyclopharm enters into Medical Imaging Joint Venture	PRICE SENSITIVE	29/07/09	105.87KB	Share
CYC	Company Update	PRICE SENSITIVE	28/04/09	100.01KB	Share
CYC	Preliminary Final Report	PRICE SENSITIVE	26/02/09	10.93MB	Share
CYC	Lodgement of application to sell Technegas in United States	PRICE SENSITIVE	22/12/08	92.45KB	Share

CYC Announcement of buy-back - Appendix 3C
29/05/18	PRICE SENSITIVE	265.23KB	Share
CYC CYC 2018 AGM Presentation
29/05/18	PRICE SENSITIVE	1.14MB	Share
CYC Managing Director's Address to Shareholders
29/05/18	PRICE SENSITIVE	179.05KB	Share
CYC Chairman's Address to Shareholders
29/05/18	PRICE SENSITIVE	380.36KB	Share
CYC Better Defining Airways Disease with Technegas
17/05/18	PRICE SENSITIVE	188.86KB	Share
CYC Cyclopharm Acquires Scandinavian Distribution Business
07/05/18	PRICE SENSITIVE	359.87KB	Share
CYC 40 Patient Milestone Achieved For Technegas USFDA Trial
29/03/18	PRICE SENSITIVE	376.93KB	Share
CYC Preliminary Final Report
26/02/18	PRICE SENSITIVE	569.46KB	Share
CYC Dividend/Distribution - CYC
26/02/18	PRICE SENSITIVE	23.99KB	Share
CYC CYC CEO Presentation 2017 Australian Microcap Conference
18/10/17	PRICE SENSITIVE	678.12KB	Share
CYC Technegas USFDA Clinical Trial - Patient Enrolment Underway
26/09/17	PRICE SENSITIVE	492.13KB	Share
CYC Cyclopharm acquires European distribution business
20/09/17	PRICE SENSITIVE	96.62KB	Share
CYC Advancing Molecular Imaging in NSW
19/09/17	PRICE SENSITIVE	118.6KB	Share
CYC Half Yearly Report and Accounts
28/08/17	PRICE SENSITIVE	1.19MB	Share
CYC Nuclear imaging trial aiming to clear up airway diagnosis
18/08/17	PRICE SENSITIVE	120.41KB	Share
CYC CYC Entitlement Offer Booklet
14/06/17	PRICE SENSITIVE	2.31MB	Share
CYC Entitlement Offer
05/06/17	PRICE SENSITIVE	1.43MB	Share
CYC CYC - Positive Results of China Clinical Trial
01/06/17	PRICE SENSITIVE	64.64KB	Share
CYC Announcement of buy-back - Appendix 3C
09/05/17	PRICE SENSITIVE	120.24KB	Share
CYC Managing Director's Address to Shareholders
09/05/17	PRICE SENSITIVE	171.02KB	Share
CYC Cyclopharm Amended 2016 Preliminary Financial Report
27/02/17	PRICE SENSITIVE	922.78KB	Share
CYC Preliminary Final Report
22/02/17	PRICE SENSITIVE	1.03MB	Share
CYC CYC 2016 PRELIMINARY HEADLINE UPDATE-RECORD RESULTS
06/02/17	PRICE SENSITIVE	108.03KB	Share
CYC CYC Achieves USFDA Agreement For Technegas Trial Design
23/11/16	PRICE SENSITIVE	125.4KB	Share
CYC Cyclopharm Business Update on Significant Milestones-CYC.AX
13/10/16	PRICE SENSITIVE	142.01KB	Share
CYC Appendix 4D and Half Year Accounts-CYC.AX
19/08/16	PRICE SENSITIVE	1.95MB	Share
CYC CYC Signs Agreement with the Canadian Association of Nuc Med-CYC.AX
27/06/16	PRICE SENSITIVE	546.06KB	Share
CYC Trading Update & Record Technegas Order Received from China-CYC.AX
21/06/16	PRICE SENSITIVE	330.68KB	Share
CYC Announcement of buy-back - Appendix 3C-CYC.AX
11/05/16	PRICE SENSITIVE	235.19KB	Share
CYC Cyclopharm to Proceed Independently with FDA Trials-CYC.AX
10/05/16	PRICE SENSITIVE	151.49KB	Share
CYC Preliminary Final Report
24/02/16	PRICE SENSITIVE	1.12MB	Share
CYC Technegas COPD Trial Update
29/01/16	PRICE SENSITIVE	289.27KB	Share
CYC Cyclopharm receives insurance settlement
31/12/15	PRICE SENSITIVE	208.49KB	Share
CYC Cyclopharm signs Term Sheet with Jubilant Draximage
14/09/15	PRICE SENSITIVE	147.71KB	Share
CYC Half Yearly Report and Accounts
26/08/15	PRICE SENSITIVE	868.83KB	Share
CYC Preliminary Final Report
19/02/15	PRICE SENSITIVE	760.57KB	Share
CYC Update on Cyclotron Facility
16/09/14	PRICE SENSITIVE	194.95KB	Share
CYC Half Yearly Report and Accounts
29/08/14	PRICE SENSITIVE	496.75KB	Share
CYC Results of Mediation
26/08/14	PRICE SENSITIVE	194.73KB	Share
CYC Cyclotron Facility Suffers Significant Water Damage
20/06/14	PRICE SENSITIVE	114KB	Share
CYCCyclopharm to cease Cyclotron commercial operations
28/03/14	PRICE SENSITIVE	267.79KB	Share
CYCPreliminary Final Report
28/02/14	PRICE SENSITIVE	567.12KB	Share
CYCJapanese Regulatory Approval received
25/10/13	PRICE SENSITIVE	212.91KB	Share
CYCHalf Yearly Report and Accounts
28/08/13	PRICE SENSITIVE	332.9KB	Share
CYCTechnegas May Facilitate Earlier Diagnosis of COPD
02/05/13	PRICE SENSITIVE	403.01KB	Share
CYCCyclopharm Develops New Nuclear Medicine Technology
18/04/13	PRICE SENSITIVE	220.55KB	Share
CYCPreliminary Final Report
26/02/13	PRICE SENSITIVE	492.14KB	Share
CYCTechnegas Clinical Trial - First Patient Enrolled
19/11/12	PRICE SENSITIVE	95.71KB	Share
CYCOffer Booklet
09/11/12	PRICE SENSITIVE	62.96KB	Share
CYCRenounceable Issue
09/11/12	PRICE SENSITIVE	66.15KB	Share
CYCTrading Halt
06/11/12	PRICE SENSITIVE	41.49KB	Share
CYCHalf Yearly Report and Accounts
30/08/12	PRICE SENSITIVE	341.41KB	Share
CYCCyclopharm to Establish Operations in Queensland
24/08/12	PRICE SENSITIVE	90.97KB	Share
CYCCyclopharm Files Claim Against ANSTO
28/06/12	PRICE SENSITIVE	87.13KB	Share
CYCPreliminary Final Report
29/02/12	PRICE SENSITIVE	329.52KB	Share
CYCCyclopharm Receives Approval from United States FDA
13/12/11	PRICE SENSITIVE	334.42KB	Share
CYCOffer Booklet for Renounceable Rights Issue
18/11/11	PRICE SENSITIVE	62.59KB	Share
CYCRenounceable Rights Issue and Sale of Unmarketable Parcels
04/11/11	PRICE SENSITIVE	61.78KB	Share
CYCRenewal of Debt Facility with National Australia Bank
03/11/11	PRICE SENSITIVE	97.31KB	Share
CYCHalf Yearly Report and Accounts
31/08/11	PRICE SENSITIVE	195.46KB	Share
CYCTrading Update
29/07/11	PRICE SENSITIVE	207.81KB	Share
CYCPreliminary Final Report
28/02/11	PRICE SENSITIVE	395.04KB	Share
CYCClinical Protocol Approval from US FDA
22/02/11	PRICE SENSITIVE	88.25KB	Share
CYCCyclopet sells commercial FDG doses
16/12/10	PRICE SENSITIVE	96.17KB	Share
CYCCyclopet receives TGA License
03/12/10	PRICE SENSITIVE	97.34KB	Share
CYCHalf Yearly Report and Accounts
31/08/10	PRICE SENSITIVE	1.38MB	Share
CYCRegulatory Approval in China
25/05/10	PRICE SENSITIVE	91.24KB	Share
CYCPreliminary Final Report
25/02/10	PRICE SENSITIVE	337.69KB	Share
CYCCyclopharm settles claim for US$1.8m
11/12/09	PRICE SENSITIVE	94.45KB	Share
CYCCyclotron delivered to Macquarie University Hospital
09/11/09	PRICE SENSITIVE	93.01KB	Share
CYCHalf Yearly Report and Accounts
27/08/09	PRICE SENSITIVE	157.57KB	Share
CYCCyclopharm enters into Medical Imaging Joint Venture
29/07/09	PRICE SENSITIVE	105.87KB	Share
CYCCompany Update
28/04/09	PRICE SENSITIVE	100.01KB	Share
CYCPreliminary Final Report
26/02/09	PRICE SENSITIVE	10.93MB	Share
CYCLodgement of application to sell Technegas in United States
22/12/08	PRICE SENSITIVE	92.45KB	Share

REFRESH

First

Add to My Watchlist

What is My Watchlist?

A personalised tool to help users track selected stocks. Delivering real-time notifications on price updates, announcements, and performance stats on each to help make informed investment decisions.

(20min delay)
Last 97.5¢		Change -0.015(1.52%)		Mkt cap ! $108.3M

Open	High	Low	Value	Volume
99.0¢	99.0¢	97.5¢	$26.70K	27.21K

Buyers (Bids)

No.	Vol.	Price($)
2	9447	97.0¢

Sellers (Offers)

Price($)	Vol.	No.
99.5¢	10000	1

View Market Depth

No.	Vol.	Price($)
2	9447	0.970
1	15000	0.965
1	1040	0.960
1	1500	0.950
1	3120	0.930

Price($)	Vol.	No.
0.995	10000	1
1.010	1239	1
1.025	7920	1
1.040	457	1
1.110	1000	1

Last trade - 12.32pm 11/08/2025 (20 minute delay)


Last 96.5¢		Change -0.015 ( 3.98 %)
Open	High	Low	Volume
98.0¢	98.5¢	96.5¢	3386
Last updated 13.46pm 11/08/2025 ?

CYC (ASX) Chart

CYCLOPHARM LIMITED - Announcements

Corporate SpotlightNot Yet Available

Announcements

Buyers (Bids)

Sellers (Offers)

Top Stories

Corporate Spotlight
Not Yet Available